Human telomerase reverse transcriptase protects hematopoietic progenitor TF-1 cells from death and quiescence induced by cytokine withdrawal

被引:13
作者
Li, S.
Ferguson, M. J.
Hawkins, C. J.
Smith, C.
Elwood, N. J.
机构
[1] Univ Melbourne, Childrens Canc Ctr, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia
[2] Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Parkville, Vic 3052, Australia
[3] Leukemia BMT Program British Columbia, Vancouver, BC, Canada
关键词
telomerase; telomere; cell cycle; hematopoiesis; survival;
D O I
10.1038/sj.leu.2404251
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Telomerase is a complex ribonucleoprotein enzyme that exhibits elevated activity in the majority of cases of human leukemia. We have previously shown that retroviral expression of the catalytic subunit of telomerase, human telomerase reverse transcriptase (hTERT), in human cord blood CD34(+) cells leads to an enhanced survival of mature hematopoietic cells. The mechanism for this pro-survival effect is not known. Here, we show that telomerase may play a role in leukemogenesis as a survival factor, independent of its role in maintaining telomere length. Retroviral expression of hTERT in the cytokine-dependent, human hematopoietic progenitor cell line, TF-1, resulted in the survival of cells following the withdrawal of cytokine, with protection from apoptosis, but did not promote unlimited replicative potential. This hTERT-mediated effect on cell survival does not involve Bcl-2 family members, results in accumulation of cells in G1 and appears to operate via autocrine expression of IL-3 and activation of the p53/ p21 pathway. Survival in the absence of cytokine stimulation was also observed following retroviral expression of hTERT in normal cord blood CD34(+) cells. This study demonstrates a novel pro-survival role for hTERT and may have important implications for the role of hTERT in the pathogenesis of leukemia and drug resistance.
引用
收藏
页码:1270 / 1278
页数:9
相关论文
共 39 条
[1]   HOXB4 overexpression mediates very rapid stem cell regeneration and competitive hematopoietic repopulation [J].
Antonchuk, J ;
Sauvageau, G ;
Humphries, RK .
EXPERIMENTAL HEMATOLOGY, 2001, 29 (09) :1125-1134
[2]   Pathways governing G1/S transition and their response to DNA damage [J].
Bartek, J ;
Lukas, J .
FEBS LETTERS, 2001, 490 (03) :117-122
[3]   Telomerase beyond telomeres [J].
Blasco, MA .
NATURE REVIEWS CANCER, 2002, 2 (08) :627-632
[4]   Extension of life-span by introduction of telomerase into normal human cells [J].
Bodnar, AG ;
Ouellette, M ;
Frolkis, M ;
Holt, SE ;
Chiu, CP ;
Morin, GB ;
Harley, CB ;
Shay, JW ;
Lichtsteiner, S ;
Wright, WE .
SCIENCE, 1998, 279 (5349) :349-352
[5]   TERT regulates cell survival independent of telomerase enzymatic activity [J].
Cao, Y ;
Li, H ;
Deb, S ;
Liu, JP .
ONCOGENE, 2002, 21 (20) :3130-3138
[6]   The hTERTα splice variant is a dominant negative inhibitor of telomerase activity [J].
Colgin, LM ;
Wilkinson, C ;
Englezou, A ;
Kilian, A ;
Robinson, MO ;
Reddel, RR .
NEOPLASIA, 2000, 2 (05) :426-432
[7]   Macrophage colony-stimulating factor-, granulocyte-macrophage colony-stimulating factor-, or IL-3-dependent survival of macrophages, but not proliferation, requires the expression of p21waf1 through the phosphatidylinositol 3-kinase/Akt pathway [J].
Comalada, M ;
Xaus, J ;
Sánchez, E ;
Valledor, AF ;
Celada, A .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (08) :2257-2267
[8]   The Bcl-2 family: roles in cell survival and oncogenesis [J].
Cory, S ;
Huang, DCS ;
Adams, JM .
ONCOGENE, 2003, 22 (53) :8590-8607
[9]   Death receptor signaling regulatory function for telomerase:: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance [J].
Dudognon, C ;
Pendino, F ;
Hillion, J ;
Saumet, A ;
Lanotte, M ;
Ségal-Bendirdjian, E .
ONCOGENE, 2004, 23 (45) :7469-7474
[10]  
Elwood Ngaire, 2004, Cancer Control, V11, P77